AFFY  Affymax Inc.




Consumer Durables


Major Pharmaceuticals

Market Cap.


Current Price

+0.00 (+0.00%)

Book Price

Overvalued by 366.75%
Financial Institution

Company Metrics

  • P/E 0.85
  • P/S 62.48
  • P/B 0.51
  • EPS 0.08
  • Dividend 0.00 / 0.00 %
  • Avg. Vol. 19,875.00
  • Shares 37.43M
  • Market Cap. 2.62M

Company Description

Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. The company is developing Hematide, which is in Phase III clinical trials for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood ... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Affymax, Inc. Announces a Special Cash Distribution and the Appointment of a ...
Business Wire (press release) - Nov 26, 2014
CUPERTINO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (OTCQB: AFFY) today announced that its Board of Directors has declared a special cash distribution to shareholders in the amount of $0.05 per share.
Affymax, Inc. (OTCMKTS:AFFY) Crashes After Losing Partner
HotStocked - Jun 17, 2014
To elaborate - some years ago, AFFY was one of the more promising biotech companies on the OTC. It had intellectual property, strong partners, funded its operations successfully, and even managed to deliver a product on the market.
Affymax Likely Worthless: Omontys Kills At Least 9x More People Than Epogen
Seeking Alpha - Aug 28, 2013
Affymax, Inc. (AFFY) is a shell company that owns potential future royalty and milestone payments associated with the recently recalled drug Omontys (peginesatide).
Affymax, Inc. (NASDAQ:AFFY) Stock Shoots Up
HotStocked - Aug 9, 2010
On the next day, investors unlocked the upward potential of AFFY stock. Additional impact on the stock rush had the company's announcement about some strategic plans of Affymax and Takeda to collaborate on the development and co-commercialization of ...
Affymax stock plunges 85 percent on drug recall
Reuters - Feb 25, 2013
Shares of Affymax Inc AFFY.O fell 85 percent after it said serious adverse reactions, including death, were reported among some of those using its sole commercial product, anemia drug Omontys.
Affymax and Takeda Announce a Nationwide Voluntary Recall of All Lots of ... - Business Wire (press release)
Affymax Announces Appointment of Herb Cross as Chief Financial Officer
Business Wire (press release) - Feb 4, 2011
PALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (NASDAQ:AFFY) today announced that Herb Cross, the company's vice president of finance and chief accounting officer, will become Affymax's chief financial officer effective March 4, 2011.
Affymax Board Announces Decision to Dissolve the Company
Business Wire (press release) - Jun 24, 2014
CUPERTINO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (AFFY), a biopharmaceutical company, today announced that its Board of Directors has approved the liquidation and dissolution of the company, subject to stockholder approval, and plans to distribute all ...
Affymax Board Approves Dissolving Troubled Company - Genetic Engineering News
How to Protect Your Retirement Plans
Benzinga - Jun 26, 2013
Imagine some unfortunately soul who invested his entire $500,000 savings into Affymax (OTC: AFFY) on February 22. On February 25, he would have lost over $425,000 due to the firm's recall of its core product.
Is It Time to Buy Illumina Inc. Stock?
Motley Fool - Mar 14, 2016
Article Info. Mar 14, 2016 at 11:39AM; Health Care. Stocks. Pacific Biosciences of California Stock Quote. Pacific Biosciences of California.
Affymax Largely Ducks Investor Suit Over Anemia Drug
Law360 (subscription) - Jan 22, 2014
Law360, Washington (January 22, 2014, 1:52 PM EST) -- A California federal judge on Tuesday trimmed a putative shareholder class action claiming Affymax Inc. and four executives misled investors about safety issues with anemia drug Omontys, ruling the ...